デフォルト表紙
市場調査レポート
商品コード
997425

慢性腎臓病(CKD)薬の世界市場

Chronic Kidney Disease (CKD) Drugs

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=129.43円
慢性腎臓病(CKD)薬の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の慢性腎臓病(CKD)薬の市場規模は、分析期間(2020年~2027年)に1.9%のCAGRで成長する見通しで、2020年の137億米ドルから、2027年には157億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つであるカルシウム拮抗剤は、分析期間中に1.8%のCAGRで成長し、34億米ドルに達すると予測されています。

当レポートは、世界の慢性腎臓病(CKD)薬市場について調査しており、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • AbbVie, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

IV. 競合

  • 企業プロファイル:42社
目次
Product Code: MCP11029

Abstract:

Global Chronic Kidney Disease (CKD) Drugs Market to Reach $15.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Chronic Kidney Disease (CKD) Drugs estimated at US$13.7 Billion in the year 2020, is projected to reach a revised size of US$15.7 Billion by 2027, growing at a CAGR of 1.9% over the analysis period 2020-2027. Calcium Channel Blockers, one of the segments analyzed in the report, is projected to record a 1.8% CAGR and reach US$3.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antihypertensives segment is readjusted to a revised 1.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.7 Billion, While China is Forecast to Grow at 3.6% CAGR

The Chronic Kidney Disease (CKD) Drugs market in the U.S. is estimated at US$3.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3 Billion by the year 2027 trailing a CAGR of 3.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.3% and 1.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.

Erythropoiesis-Stimulating Agents (ESAs) Segment to Record 2.6% CAGR

In the global Erythropoiesis-Stimulating Agents (ESAs) segment, USA, Canada, Japan, China and Europe will drive the 2.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.6 Billion in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.1 Billion by the year 2027, while Latin America will expand at a 3.4% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -

  • AbbVie, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Chronic Kidney Disease (CKD) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Antihypertensives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Antihypertensives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Antihypertensives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Erythropoiesis-Stimulating Agents (ESAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Erythropoiesis-Stimulating Agents (ESAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Erythropoiesis-Stimulating Agents (ESAs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 22: USA Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 25: Canada Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 28: Japan Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Japan Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Japan 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 31: China Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: China Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: China 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 34: Europe Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: Europe Historic Review for Chronic Kidney Disease (CKD) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Europe 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 37: Europe Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Europe Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Europe 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 40: France Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: France Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: France 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 43: Germany Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Germany Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Germany 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 46: Italy Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Italy Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Italy 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 49: UK Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: UK Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: UK 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 52: Spain Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Spain Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Spain 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 55: Russia Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Russia Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Russia 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 58: Rest of Europe Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Rest of Europe Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Rest of Europe 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 61: Asia-Pacific Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 62: Asia-Pacific Historic Review for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 64: Asia-Pacific Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Asia-Pacific Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 67: Australia Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Australia Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Australia 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 70: India Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: India Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: India 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 73: South Korea Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: South Korea Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: South Korea 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 76: Rest of Asia-Pacific Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Rest of Asia-Pacific Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Rest of Asia-Pacific 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 79: Latin America Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 80: Latin America Historic Review for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Latin America 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 82: Latin America Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Latin America Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Latin America 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 85: Argentina Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Argentina Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Argentina 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 88: Brazil Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Brazil Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Brazil 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 91: Mexico Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Mexico Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Mexico 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 94: Rest of Latin America Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of Latin America Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of Latin America 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 97: Middle East Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 98: Middle East Historic Review for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Middle East 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 100: Middle East Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Middle East Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Middle East 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 103: Iran Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Iran Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Iran 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 106: Israel Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Israel Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Israel 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 109: Saudi Arabia Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Saudi Arabia Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Saudi Arabia 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 112: UAE Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UAE Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: UAE 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 115: Rest of Middle East Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Rest of Middle East Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Rest of Middle East 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 118: Africa Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Africa Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Africa 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Calcium Channel Blockers, Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Beta Blockers, ACE Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42